Liz Beatty is chief strategy officer, Inato, where the company is building the world’s first clinical trial platform to create greater visibility, access, and engagement across a more diverse population of doctors and their patients.
She is focused on advancing Inato’s corporate strategy, developing partnerships, and driving growth in North America.
Previously, Liz headed digital clinical trials at Bristol-Myers Squibb, where she led digital innovation efforts across global clinical operations.
Liz Beatty is chief strategy officer, Inato, where the company is building the world's first clinical trial platform to create greater visibility, access, and engagement across a more diverse population of doctors and their patients.
She is focused on advancing Inato’s corporate strategy, developing partnerships, and driving growth in North America.
Previously, Liz headed digital clinical trials at Bristol-Myers Squibb, where she led digital innovation efforts across global clinical operations.
Minority and marginalized communities have historically been underrepresented in local and federal governments and in dozens of private sectors globally. Pharma is no different; there exists a steep chasm that drugmakers have yet to bridge concerning research and trials. The longer this gulf exists, the harder it becomes to address – the feelings of mistrust, resentment, and disenfranchisement only get harder to overcome with time.
